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Abstract
Background: Dopaminergic pathways could be involved in the pathophysiology of myofascial temporomandibular
disorders (M-TMD). This study investigated plasma levels of dopamine and serotonin (5-HT) in patients with M-TMD
and in healthy subjects.
Methods: Fifteen patients with M-TMD and 15 age- and sex-matched healthy subjects participated. The patients
had received an M-TMD diagnosis according to the Research Diagnostic Criteria for TMD. Perceived mental stress,
pain intensity (0–100-mm visual analogue scale), and pressure pain thresholds (PPT, kPa) over the masseter muscles
were assessed; a venous blood sample was taken.
Results: Dopamine in plasma differed significantly between patients with M-TMD (4.98 ± 2.55 nM) and healthy controls
(2.73 ± 1.24 nM; P < 0.01). No significant difference in plasma 5-HT was observed between the groups (P = 0.75). Patients
reported significantly higher pain intensities (P < 0.001) and had lower PPTs (P < 0.01) compared with the healthy
controls. Importantly, dopamine in plasma correlated significantly with present pain intensity (r = 0.53, n = 14, P < 0.05)
and perceived mental stress (r = 0.34, n = 28, P < 0.05).
Conclusions: The results suggest that peripheral dopamine might be involved in modulating peripheral pain.
This finding, in addition to reports in other studies, suggests that dopaminergic pathways could be implicated
in the pathophysiology of M-TMD but also in other chronic pain conditions. More research is warranted to
elucidate the role of peripheral dopamine in the pathophysiology of chronic pain.
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Background
Dopamine and 5-hydroxytryptamine (5-HT) are neuro-
transmitters found in the central (CNS) and peripheral
nervous systems, and in plasma. In the CNS, dopamine
is involved in motor control, cognition, and the reward
system [1], but possibly also in pain perception [2].
Primarily dopaminergic neurons synthesize dopamine in
the CNS [1], while neuronal fibers, adrenal medulla, and
neuroendocrine cells synthesize dopamine in the periph-
eral nervous system [1]. Goldstein and Holmes have
observed that dopamine in plasma is primarily related to
sympathetic activity; that is, rises in sympathetic activity
increase release of precursors to dopamine and nor-
epinephrine [3]. Rubi and Maechler report in their
mini-review that dopamine in plasma are elevated in
situations that involve psychological stress, muscle exer-
cise, or hypovolemia [1].
Bruxism, “a repetitive jaw-muscle activity character-
ized by clenching or grinding of the teeth and/or by
bracing or thrusting the mandible” [4], has been linked to
disturbances in the central dopaminergic system [5], as
has another motor function disorder, Parkinson’s disease
[6]. Aside from motor function-related disturbances, the
most self-reported symptom in patients with Parkinson’s
disease is pain [7]. It has also been suggested that alter-
ations in dopaminergic neurotransmission might be
involved in burning mouth syndrome [8, 9], fibromyalgia
[10], and chronic orofacial pain [8, 9]. The literature
indicates that the dopaminergic system may be involved
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in central pain modulation, but the role of dopamine at
the peripheral level in relation to pain is unknown.
Graven-Nielsen et al. found 5-HT involvement in pain
transmission at the peripheral and central levels [11].
Several other studies have demonstrated that patients
with chronic myalgia, including myofascial temporo-
mandibular disorders (M-TMD) have significantly higher
interstitial concentrations of 5-HT than healthy controls
[12–16] and that high 5-HT levels are correlated with
muscle pain and allodynia [14–17]. In addition, in patients
with fibromyalgia, Ernberg et al. found that high levels of
plasma 5-HT in relation to serum 5-HT may be associated
with pain discomfort and high levels of anxiety [18].
Amongst others, autonomic and psychosocial factors
have been suggested as risk factors for TMD [19, 20].
Maixner et al. observed that TMD patients have a sig-
nificantly altered autonomic function compared with
healthy controls at rest and in stressful situations [20].
Thus, it is plausible that activity in the sympathetic ner-
vous system of these patients is altered, and if dopamine
in plasma is a potential indicator of such activity, they
could be implicated in M-TMD.
The role of peripheral dopamine and 5-HT and their
association with pain in patients with M-TMD is so far
unknown. The aim of this study was to investigate
plasma levels of dopamine and 5-HT in patients with
M-TMD and healthy controls. Two hypotheses were
tested: (i) patients with M-TMD have higher levels of
dopamine and 5-HT in plasma than healthy subjects,
and (ii) pain intensity and the pressure pain threshold




Fifteen patients with M-TMD (mean age: 31.8 ± 13.4 years)
and an age- and gender-matched control group (mean age:
31.6 ± 12.4 years) participated in this study. Eleven females
and four males participated in each group. Both groups
were participating in other studies [12, 21, 22]. The control
group was recruited from staff at Malmö University, while
the patients were recruited among consecutive patients
referred to the Department of Orofacial Pain and Jaw
Function, Faculty of Odontology, Malmö University,
Malmö, Sweden and, after a clinical examination, had been
diagnosed with M-TMD [23]. One author (AD) examined
the patients to confirm a diagnosis of M-TMD and the
control group to confirm that the subjects were healthy.
The inclusion criteria for the M-TMD group were (i)
age > 18 years, (ii) a diagnosis of M-TMD pain [23], (iii)
moderate or more severe pain in the masseter muscles
upon palpation at the clinical examination and on the
experimental day, and (iv) continuous or persistent pain
in the jaw muscles for more than 6 months.
Inclusion criteria for the healthy controls were (i) age >
18 years, (ii) healthy, and (iii) no orofacial pain
complaints.
Exclusion criteria for both groups were conditions that
could influence pain sensitivity, such as systemic inflam-
matory connective tissue diseases (e.g., rheumatoid arth-
ritis); whiplash-associated disorders; chronic widespread
muscle pain conditions (e.g., fibromyalgia); neuropathic
pain or neurological disorders (e.g., oromandibular dys-
tonia); pain of dental origin; pregnancy or lactation; high
blood pressure; and ongoing dental treatment. Another
exclusion criterion was medication that could interfere
with the blood analysis or pain sensitivity (e.g., anti-
coagulant treatment and analgesic consumption within
1 week before the experiment, for example, of paraceta-
mol, NSAIDs, salicylate drugs, or opioids) or that could
influence pain perception (e.g., anti-depressants or anti-
epileptic drugs). Exclusion criteria were assessed in each
subject by taking a medical history.
Ethics approval of the study
This study was conducted at the Department of Orofacial
Pain and Jaw Function at Malmö University. The guide-
lines of the Helsinki Declaration were followed, and the
Regional Ethics Review Board at Lund University ap-
proved the study (2010/31). Before participation, subjects
signed an informed-consent form and were informed that
they could refrain from the study at any time without any
consequences. After completion of participation, subjects
were financially compensated.
Study design
The 1-h clinical examination, scheduled at 8 am or 1 pm
comprised an examination according to the RDC/TMD;
collection of a venous blood sample for analysis of dopa-
mine and 5-HT in plasma, and assessment of present
pain intensity and the pressure pain threshold (PPT).
Throughout the trial, subjects sat upright in a dental
chair with head support. One operator (AD) conducted
the examination.
Blood sampling
Venous blood samples were collected in 3-mL EDTA
Vacutainers (Becton, Dickinson, and Company; Franklin
Lake, NJ, USA). Directly after withdrawal, the samples
were centrifuged (2000 g, +20 °C) for 10 min and the
plasma was transferred into Eppendorf tubes and stored
at −70 °C until analysis.
Assessment of pressure pain threshold, present pain
intensity, and perceived mental stress
An electronic algometer (Somedic Sales AB, Hörby,
Sweden) was used to assess the PPT, defined as the
amount of pressure (kPa) needed to produce the
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slightest sensation of pain. A 1-cm2 probe was applied
to the lower attachment of the right masseter muscle
with a constant pressure of 30 kPa/s. The mean of three
measurements made at 60-s intervals at the same area
was calculated [24]. The reliability of PPT measurements
on the masseter muscle was previously found to be
acceptable [25].
A 100-mm visual analogue scale (VAS) was used to
assess pain intensity (anchor definitions: no pain and
worst imaginable pain).
The 10-item perceived stress scale (PSS-10) was used to
assess perceived mental stress during the past month in the
participants. The PSS-10 measures to what degree various
situations in life are perceived as stressful. Reliability and
validity of the Swedish version of PSS-10 is good [26].
Analysis of dopamine and 5-HT
On the day of analysis, the plasma samples were thawed
on ice. Evolute WCW solid phase extraction columns
(25 mg) from Biotage (Uppsala, Sweden) were used to
extract dopamine and 5-HT from the plasma. The sam-
ples were prepared using the manufacturer’s recom-
mended extraction protocol. After the analytes were
eluted from the columns, the fractions were dried using
a SpeedVac system and dissolved in the mobile phase
used for high performance liquid chromatography with
electrochemical detection (HPLC-EC). HPLC analyses
were conducted as previously described [13].
Statistics
All statistical analyses were done using the Statistical
Package for the Social Sciences for Windows (SPSS,
v.20; IBM). Analyses were performed two-tailed at a sig-
nificance level of 5 %. All variables are expressed as
means and SDs unless otherwise stated. The Shapiro-
Wilk’s test was used to test the data for normality.
Present pain intensity, PPT, perceived mental stress, and
the levels of dopamine in plasma were normally distrib-
uted, while 5-HT levels in plasma were normally distrib-
uted after Ln-transformation. Parametric statistics were
used in all statistical analyses excluding those of categor-
ical variables or in analysis of M-TMD duration, since
this variable was not normally distributed.
The Mann-Whitney U-test was used to determine sig-
nificant differences between groups regarding duration
of M-TMD (mos) and number of muscle and temporo-
mandibular joints sites with pain on palpation.
Independent samples t-tests were used to investigate
significant differences in age, pain intensity, PPT, per-
ceived mental stress, and dopamine and 5-HT in plasma
between groups. To test for significant correlations
between pain intensity, PPT, perceived mental stress,
and plasma dopamine, or 5-HT in each group, the
Pearson’s correlation test (adjusted for multiple testing
with Bonferroni correction) was used.
It has been suggested that plasma levels of dopamine
and epinephrine are equivalent [1], so the sample size
calculation was based on the mean ± SD of the plasma
level of epinephrine in healthy subjects, 0.337 ± 0.106
nM [27], using β = 0.80 and α = 0.05. A power analysis
found that 11 subjects in each group would suffice to
detect a mean difference of 1 SD in dopamine level.
Results
Clinical characteristics of the study sample
Table 1 presents the clinical characteristics of the study
sample.
Dopamine and 5-HT in plasma
Dopamine in plasma differed significantly between
groups (P < 0.01), being higher for the patients with
M-TMD than the healthy subjects. No significant
group differences for plasma 5-HT were observed (P =
0.75; Fig. 1).
Present pain intensity, pressure pain threshold, and
perceived mental stress
Patients with M-TMD had significantly higher present
pain intensity (P < 0.001; Fig. 2) and perceived mental
stress (P < 0.05; Fig. 3) and significantly lower PPTs com-
pared with healthy subjects (P < 0.01; Fig. 2).
Correlations
In the M-TMD group, present pain intensity correlated
significantly with dopamine in plasma (r = 0.53, n = 14,
P < 0.05), but not with 5-HT (r = −0.02, n = 14, P > 0.05).
A significant correlation was observed between dopa-
mine in plasma and perceived mental stress for the
group as a whole (r = 0.34, n = 28, P < 0.05). Present pain
intensity correlated significantly with PPT (r = −0.42,
n = 30, P < 0.01) and perceived mental stress (r = 0.46,
n = 29, P < 0.01). 5-HT did not correlate significantly
with present pain intensity (r = 0.005, n = 27, P > 0.05),
PPT (r = −0.011, n = 27, P > 0.05), or perceived mental
stress (r = 0.104, n = 27, P > 0.05).
Discussion
The main findings of this study were that (i) dopamine
in plasma was significantly higher in patients with M-
TMD than in healthy subjects; and correlated signifi-
cantly with present pain intensity and perceived mental
stress, (ii) present pain intensity correlated significantly
with PPT and perceived mental stress, (iii) 5-HT in
plasma did not differ significantly between groups, and
did not correlate significantly with present pain intensity,
PPT, or perceived mental stress.
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Previous studies have suggested that dopaminergic
neurotransmission is altered at a central level in patients
with chronic pain conditions [8–10]. But the novel find-
ing in this study that dopamine in plasma correlated
significantly with present pain intensity in the masseter
muscle suggests involvement of dopamine in pain
modulation, at not only a central but a peripheral level
as well. It is known that dopamine targets D1 and D2 re-
ceptors at the central level. Activation of the D1 receptor
leads to formation of cAMP [28] and subsequent activa-
tion of protein kinase A, which sensitizes tetrodotoxin
(TTX)-resistant Na+ channels [29], causing a pain re-
sponse. On the other hand, activation of D2 receptors
counteracts cAMP formation [28], possibly inhibiting
sensitization of TTX-resistant Na + channels [29]. Such
inhibition has been observed in animal studies where
administration of D2 dopamine receptor antagonists in
striatal neurons reduces pain [30, 31]. On the other
hand, however, it is believed that patients with chronic
pain, such as burning mouth syndrome and atypical
facial pain, exhibit higher densities of D2 receptors in
the putamen compared with healthy subjects [8, 9].
Thus, it seems that D2 receptors have both a pain-
suppressing and a pain-enhancing effect. Hypothetically,
chronic activity in the dopaminergic system, possibly
due to chronic pain, could cause these effects; in healthy
individuals, the dopaminergic system is not chronically
activated, so D2 receptors seem to be primarily associ-
ated with pain suppression.
An experimental animal study of Tambeli et al.
demonstrated the existence of D1 receptors in the per-
iphery [32]. The researchers [32] showed that dopamine
injections provoked a nociceptive response, while the
selective D1-receptor antagonist SCH23390 reversed this
response. Similarly, 5-HT injections also created a
nociceptive response that was reversed by the same D1-
receptor antagonist [32]. Thus, it seems that 5-HT in
the periphery provokes a release of dopamine, which in
turn targets D1 receptors, thus causing a nociceptive
response. This is particularly interesting since patients
Table 1 Clinical characteristics of the study sample





Age (yrs) 31.8 ± 13.4 31.6 ± 12.4 0.966 Independent samples t-test
Duration of M-TMD (months) 58.6 ± 60.3 0.0 ± 0.0 <0.001 Mann-Whitney U test
No. of muscle sites with pain on palpation (max. 20) 14 (8) 2 (2) <0.001 Mann-Whitney U test
No. of TMJ sites with pain on palpation (max. 4) 1 (1) 0 (0) <0.001 Mann-Whitney U test
Perceived mental stress (PSS-10) 16.6 ± 5.9 12.1 ± 3.6 <0.05 Independent samples t-test
Self-reported awake bruxism 11 3
Self-reported sleep bruxism 11 7
Blood sampling at 8 am 8 8
Blood sampling at 1 pm 7 7
Mean ± SD, age (yrs), duration of M-TMD (mos), and perceived mental stress; median (interquartile range) number of muscle and temporomandibular joint (TMJ)
sites with pain on palpation; frequency of self-reported awake and sleep bruxism, and blood sampling time, in 15 patients with M-TMD and 15 healthy subjects
Fig. 1 Mean ± SD plasma concentration of dopamine and serotonin (5-HT) in 15 patients with M-TMD and 15 healthy controls. Significant differences
between groups, **P < 0.01
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with M-TMD have significantly higher levels of intersti-
tial 5-HT than healthy controls [14–16, 22]. Thus,
human D1 receptors could possibly be activated by the
same indirect mechanism observed by Tambeli et al.
[32], contributing to the facilitation of pain. In other
words, it is possible that dopamine is involved in the
pathophysiology of M-TMD at a peripheral level, espe-
cially since dopamine in plasma was significantly corre-
lated with present pain intensity.
The patients with M-TMD reported sleep bruxism and
awake bruxism more often than the healthy subjects.
One thought is that these bruxism habits influenced the
results of the present study, since bruxism has been
linked to the central dopaminergic system [5]. This is
unlikely, however, since central dopamine do not pass
the blood-brain barrier and is therefore differed from
peripheral dopamine [1].
Circadian variation in plasma dopamine levels has
been reported in humans [33], and could influence the
results. In the present study, equal numbers of patients
with M-TMD and healthy subjects were scheduled at
8 am and 1 pm. The influence of circadian variation on
plasma dopamine levels in this study should thus be
minimal.
The hypothesis that patients with M-TMD would have
significantly higher levels of 5-HT in plasma than
healthy subjects was not confirmed. Ernberg et al.
showed that a high level of 5-HT in plasma relative to in
serum was significantly correlated with pain in patients
with fibromyalgia [18] and that serum levels of 5-HT
were significantly correlated with allodynia in patients
with M-TMD [14–16]. It must be emphasized that blood
plasma analyses measure the free fraction of 5-HT, while
serum analyses reflect the total amount of 5-HT.
Patients with M-TMD have higher levels of interstitial 5-
HT in the masseter muscles compared with healthy
controls [22], thus it was hypothesized that the free
fraction of 5-HT (plasma) would be significantly higher
in these patients, due to an increased release from the
thrombocytes, but this was not confirmed and needs to
be further investigated. One explanation for these con-
flicting results may be that the patients with M-TMD in
our study had localized pain in the masticatory muscles,
while in the Ernberg et al. study [18], the patients had
wide spread pain, that is, fibromyalgia.
In the present study, patients with M-TMD had sig-
nificantly higher levels of perceived mental stress than
healthy controls, which is in line with findings from
other studies [34, 35]. We also found that perceived
mental stress correlated significantly with present pain
intensity and dopamine in plasma. A likely possibility is
that M-TMD pain is a potential stressor. This may lead
to mental stress and activation of the sympathetic
nervous system (i.e., two factors that are reported to be
risk factors for M-TMD pain [20, 36] with subsequent
peripheral release of dopamine. Measuring heart rate
variability is one way to assess sympathetic activity [37],
but this was not done in the present study. On the other
hand, dopamine in plasma is mainly regulated by activity
in the sympathetic nerves [3]. The results of the present
Fig. 2 Mean ± SD pressure pain threshold (kPa), and present pain intensity (VAS 0–100) assessed in 15 patients with M-TMD and 15 healthy controls.
Significant differences between groups, **P < 0.01; ***P < 0.001
Fig. 3 Mean ± SD perceived mental stress assessed in 15 patients
with M-TMD and 15 healthy controls. Significant differences between
groups, * P < 0.05
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study showed a significant correlation between dopa-
mine in plasma and perceived mental stress, which
supports the suggestion that peripheral dopamine is
mainly regulated by sympathetic activity [3].
We observed that the patients with M-TMD had
significantly lower PPTs in the masseter muscle than
healthy controls, which is in line with the results of
several other studies (e.g., [38, 39]. This further confirms
the generally accepted knowledge that, apart from cen-
tral mechanisms, peripheral mechanisms are involved in
the pathophysiology of M-TMD [40]. 5-HT is involved
in peripheral sensitization, and the level of interstitial
5-HT is significantly increased in M-TMD patients
compared with healthy controls [14–16, 22]. It is believed
that 5-HT may provoke a peripheral dopamine release
[32] that can facilitate a pain response by sensitizing
tetrodotoxin (TTX)-resistant Na+ channels [29]. There-
fore, it is possible that peripheral dopamine contributes to
peripheral sensitization, and could be an explanation for
the lower PPTs observed in M-TMD patients compared
with the healthy controls.
A limitation of the study is that the participants not
were asked about present perceived mental stress in the
experimental session. Sex hormones can alter pain levels
[41], and a limitation is that female participants were
not queried about menstrual cycle phase. It is, however,
very likely that the females were in different phases of
the menstrual cycle, which would negate any effects. A
strength of this study is that the present findings are the
first to highlight that peripheral dopamine could be in-
volved in peripheral pain modulation.
Conclusions
In conclusion, the novel finding of the present study that
peripheral dopamine may be involved in peripheral pain
modulation means (indicates) that peripheral dopamine
could be implicated in the pathophysiology of M-TMD
and other chronic pain conditions. But, whether the
increased level of peripheral dopamine is a consequence
of pain or mental stress is not known. More research is
needed to further understand the role and mechanisms
of peripheral dopamine in chronic pain and mental
stress.
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